Type 2 diabetes mellitus (T2DM) is known to be associated with a 33% greater risk of hospitalization for heart failure (HF) and an increase in the risk of cardiovascular and overall death.1 Patients with coexisting T2DM and chronic kidney disease (CKD) are at further risk of HF and ischemic events t

Atrial fibrillation, a distinct form of cardiovascular disease (CVD), is common in chronic kidney disease (CKD) patients.¹ It increases the risk of CKD patients developing stroke.² Intervention with warfarin is prevalent in patients with atrial fibrillation,

Secondary hyperparathyroidism (SHPT) is a very common condition in patients with chronic kidney disease (CKD).^1,2 Cinacalcet, a calcimimetic that is commonly used to treat patients with SHPT, has been recommended by well-recognized guidelines but appears to have some shortfalls with non-adherence issues.^3,4